Pegylated tissue kallikrein, and preparation method therefor and uses thereof
US10052368B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 9, 2014 |
| Grant date | Aug 21, 2018 |
| Priority date | — |
| Expiry date | Feb 14, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21035
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to polyethylene glycol (PEG) modified protein drugs, and a PEGylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in SEQ ID No. 1 or SEQ ID No. 2, and the tissue kallikrein may be natural or recombinant. The PEG has a molecular weight of 20 to 40 kDa, and is conjugated to the N-terminal primary amino of the tissue kallikrein. In addition to the advantages of significantly extended half-life, significantly reduced immunogenicity and stable and uniform structure, the biological activity of the PEGylated KLK1 provided in the present invention is improved to a higher extent, which is more significant in the treatment of cerebral apoplexy and diabetic nephropathy in particular.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.